{"id":48,"count":6,"description":"<div class=\"scroll-box\">\r\n<h2 style=\"text-align: center\">GLP-1-peptiidide uurimine: teadusuuringute rakendused ainevahetuses ja s\u00f6\u00f6giisu regulatsioonis<\/h2>\r\n<em>GLP-1 peptiidid on uurimis\u00fchendite kategooria, mida uuritakse nende m\u00f5ju t\u00f5ttu veresuhkru regulatsioonile, s\u00f6\u00f6giisu p\u00e4rssimisele ja ainevahetuse tasakaalule. Need peptiidid j\u00e4ljendavad v\u00f5i tugevdavad gl\u00fckagonilaadse peptiid-1 toimet \u2013 hormooni, mis m\u00e4ngib keskset rolli gl\u00fckoosi hom\u00f6ostaasis ja energia tarbimises. Laboritingimustes uuritakse GLP-1 peptiide sageli nende potentsiaali t\u00f5ttu rasvumise, 2. t\u00fc\u00fcpi diabeedi ja kaaluhalduse mudelites. <\/em>\r\n\r\nGLP-1 peptides are a class of research compounds that mimic or enhance the activity of glucagon-like peptide-1, a hormone involved in appetite control, insulin secretion, and glucose metabolism. In scientific studies, these peptides are explored for their ability to suppress hunger, promote fat loss, and regulate blood sugar levels, making them a major focus in research targeting obesity, type 2 diabetes, and other metabolic disorders.\r\n\r\nGLP-1 receptor agonists work by activating incretin pathways (GLP-1, GIP, and glucagon receptors), which collectively help improve insulin sensitivity, slow gastric emptying, reduce food intake, and increase metabolic expenditure. More advanced compounds in this class also target multiple receptors to enhance metabolic effects, offering new possibilities for studying complex weight-related mechanisms in lab settings.\r\n\r\n<em><strong>Lahti\u00fctlus: <\/strong>K\u00f5ik siin viidatud GLP-1 peptiidid on m\u00f5eldud kasutamiseks ainult laboriuuringutes. K\u00f5ik mainitud inimestega seotud tulemused p\u00f5hinevad \u00fcksnes loomkatsete v\u00f5i kliiniliste uuringute andmetel ning neid ei tohi t\u00f5lgendada meditsiinilise n\u00f5uande ega ravisoovitustena.<\/em>\r\n<h2>Mis on GLP-1 retseptori agonisti peptiidid?<\/h2>\r\nGLP-1 receptor agonist peptides are synthetic compounds designed to replicate or enhance the effects of glucagon-like peptide-1 (GLP-1), an incretin hormone released by the gut after eating. In research settings, GLP-1 is known for its ability to stimulate insulin secretion, suppress appetite, slow gastric emptying, and regulate blood sugar. However, the natural hormone breaks down quickly in the body, prompting the development of longer-lasting analogs for laboratory use.\r\n\r\nModern GLP-1 peptides are engineered for increased stability and often include multi-receptor activity. In addition to GLP-1 activation, some of these peptides also target:\r\n<ul>\r\n \t<li><strong>GIP (gl\u00fckoosist s\u00f5ltuv insuliinotroopne pol\u00fcpeptiid):<\/strong> T\u00f5stab insuliini vabanemist ja m\u00f5jutab rasvade ainevahetust<\/li>\r\n \t<li><strong>Gl\u00fckagooni retseptorid:<\/strong> Soodustab rasva oks\u00fcdatsiooni, termogeneesi ja energiakulu<\/li>\r\n<\/ul>\r\nNeed kombineeritud toimed teevad GLP-1 retseptori agonistid v\u00e4\u00e4rtuslikeks prekliinilistes uuringumudelites, mis on suunatud:\r\n<ul>\r\n \t<li>Kaalukaotus ja s\u00f6\u00f6giisu v\u00e4hendamine<\/li>\r\n \t<li>Rasvumine ja metaboolne s\u00fcndroom<\/li>\r\n \t<li>Insuliiniresistentsus ja gl\u00fckoosi hom\u00f6ostaas<\/li>\r\n \t<li>Rasvamassi ja energiatasakaalu uuringud<\/li>\r\n<\/ul>\r\nSelles uurimiskategoorias kasutatakse sageli selliseid peptiide nagu semaglutiid, tirsepatiid ja retatrutiid nende tugeva ainevahetust m\u00f5jutava ja kaalu langetava toime t\u00f5ttu.\r\n<h2>GLP-1 peptiidide toimemehhanismid<\/h2>\r\nGLP-1 receptor agonist peptides work by mimicking or enhancing natural gut hormones that regulate hunger, insulin release, and energy metabolism. Each peptide in this category acts on different combinations of receptors to drive metabolic effects. Here's a breakdown of the mechanisms by individual peptide:\r\n\r\n<strong>Semaglutiid<\/strong>\r\n<ul>\r\n \t<li>GLP-1 retseptori agonist semaglutiid j\u00e4ljendab looduslikke inkretiinhormoone.<\/li>\r\n \t<li>See aeglustab mao t\u00fchjenemist, pikendades t\u00e4isk\u00f5hutunnet ja v\u00e4hendades kalorite tarbimist.<\/li>\r\n \t<li>Stimuleerib insuliini sekretsiooni vastusena gl\u00fckoosile ja alandab veresuhkru taset.<\/li>\r\n \t<li>Selle pika toimeajaga koostis v\u00f5imaldab uuringumudelites manustamist \u00fcks kord n\u00e4dalas, tagades retseptorite stabiilse aktiveerimise pika aja jooksul.<\/li>\r\n<\/ul>\r\n<strong>Tirtsepatiid<\/strong>\r\n<ul>\r\n \t<li>Nii GLP-1 kui ka GIP (gl\u00fckoosist s\u00f5ltuva insuliinotroopse pol\u00fcpeptiidi) retseptorite dualistlik agonist.<\/li>\r\n \t<li>Parandab insuliinitundlikkust ja -sekretsiooni, moduleerides samal ajal gl\u00fckagooni taset.<\/li>\r\n \t<li>Surub tugevalt isu alla ja parandab gl\u00fckeemilist kontrolli, mis viib m\u00e4rkimisv\u00e4\u00e4rse kaalulanguseni.<\/li>\r\n \t<li>Kliinilistes uuringutes SURPASS edestas tirsepatiid semaglutiidi kehakaalu ja veresuhkru alandamisel.<\/li>\r\n<\/ul>\r\n<strong>Retatrutiid<\/strong>\r\n<ul>\r\n \t<li>GLP-1-, GIP- ja gl\u00fckagooniretseptoreid m\u00f5jutav kolmikretseptori agonist.<\/li>\r\n \t<li>Aktiveerib gl\u00fckagooni rajad, et suurendada energiakulu ja basaalset ainevahetust.<\/li>\r\n \t<li>Soodustab lipol\u00fc\u00fcsi ja rasvade oks\u00fcdatsiooni, muutes selle \u00fcheks tugevaimaks keharasva v\u00e4hendamiseks uuritud peptiidiks.<\/li>\r\n \t<li>Varased uuringud inimestel n\u00e4itavad suuremat kaalulangust kui teised GLP-1-p\u00f5hised \u00fchendid.<\/li>\r\n<\/ul>\r\nKoos kujutavad need peptiidid endast laboriuuringutes v\u00f5imsat metaboolsete regulaatorite klassi, mis pakuvad \u00fclevaadet s\u00f6\u00f6giisu kontrollist, insuliini d\u00fcnaamikast ja energia tasakaalust.\r\n<h2>Uuringud ja kliinilised leiud<\/h2>\r\nGLP-1-peptiidid nagu semaglutiid, tirsepatiid ja retatrutiid on oma tugeva m\u00f5ju t\u00f5ttu kaalulangusele, s\u00f6\u00f6giisu regulatsioonile ja gl\u00fckoositaseme kontrollile muutnud ainevahetusuuringuid. Neid k\u00f5iki on uuritud ulatuslikes kliinilistes ja laboratoorsetes uuringutes, mille tulemused on olnud j\u00e4rjepidevalt tugevad:\r\n<h3>Semaglutiid<\/h3>\r\n<ul>\r\n \t<li>STEP-i kliinilistes uuringutes kaotasid diabeedita \u00fclekaalulised osalejad 68 n\u00e4dala jooksul keskmiselt ~15% oma kehakaalust.<\/li>\r\n \t<li>Olulisi v\u00e4henemisi t\u00e4heldati ka v\u00f6\u00f6\u00fcmberm\u00f5\u00f5dus, t\u00fchja k\u00f5hu insuliinitasemes ja p\u00f5letikumarkerites.<\/li>\r\n \t<li>Osalejad teatasid s\u00f6\u00f6giisu v\u00e4henemisest m\u00f5ne p\u00e4eva jooksul, mis parandas pikaajalistes uuringuprotokollides ravile kuulekust.<\/li>\r\n<\/ul>\r\n<h3>Tirtsepatiid<\/h3>\r\n<ul>\r\n \t<li>SURMOUNT-1 uuringus t\u00e4heldati 72 n\u00e4dala jooksul kehakaalu langust ligikaudu 22,51 TP3T v\u00f5rra.<\/li>\r\n \t<li>Tirsepatiid parandas ka HbA1c taset, insuliinitundlikkust ja lipiidide profiili.<\/li>\r\n \t<li>Selle kahekordne GIP-i ja GLP-1 aktiivsus tegi selle otsestes v\u00f5rdlusuuringutes paremaks v\u00f5rreldes pelgalt GLP-1 agonistidega.<\/li>\r\n \t<li>Uuringud n\u00e4itavad kasu nii diabeetiliste kui ka mittediabeetiliste ainevahetuse mudelite puhul.<\/li>\r\n<\/ul>\r\n<h3>Retatrutiid<\/h3>\r\n<ul>\r\n \t<li>II faasi uuring (2023) n\u00e4itas \u00fclekaalulistel ja rasvunud osalejatel kuni 24,21 TP3T rasva kadu, mis on seni suurim tulemus inkretiinide r\u00fchmas.<\/li>\r\n \t<li>Gl\u00fckagooni retseptori aktiveerimise kaudu suurendas see energiakulu ja rasvade oks\u00fcdatsiooni rohkem kui pelgalt GLP-1\/GIP mehhanismid.<\/li>\r\n \t<li>Samuti on t\u00f5estatud kasulik m\u00f5ju verer\u00f5hule, trigl\u00fctseriididele ja maksarasvale.<\/li>\r\n<\/ul>\r\n<strong>\u00dcldised j\u00e4reldused<\/strong>\r\n\r\nK\u00f5ik kolm peptiidi n\u00e4itavad j\u00e4rjepidevalt:\r\n<ul>\r\n \t<li>Kiire s\u00f6\u00f6giisu p\u00e4rssimine<\/li>\r\n \t<li>V\u00e4henenud rasvamass, v\u00f6\u00f6\u00fcmberm\u00f5\u00f5t ja t\u00fchja k\u00f5hu insuliin<\/li>\r\n \t<li>Paranenud kardiometaboolsed markerid (kolesterool, verer\u00f5hk, CRP)<\/li>\r\n \t<li>Pikad poolestusajad teevad neist ideaalsed igan\u00e4dalaseks v\u00f5i \u00fcle-n\u00e4dalaseks teadusuuringute doseerimiseks<\/li>\r\n<\/ul>\r\nNeed leiud on kindlustanud GLP-1 retseptori agonistid rasvumise ja ainevahetuse uuringute nurgakiviks.\r\n<h2>Ohutus- ja regulatiivsed \u00fclevaated<\/h2>\r\nGLP-1 peptide research continues to evolve, with several compounds already approved for clinical use and others in advanced trial phases:\r\n\r\nSemaglutide is FDA-approved for both type 2 diabetes (as Ozempic) and chronic weight management (as Wegovy). It is widely studied in metabolic models and has a well-documented safety profile in both diabetic and non-diabetic populations.\r\n\r\nTirzepatide, a dual GLP-1\/GIP agonist, is also FDA-approved for type 2 diabetes (as Mounjaro) and is under review for obesity-related approvals, following positive SURMOUNT trial data.\r\n\r\nRetatrutide, the triple agonist (GLP-1, GIP, glucagon), remains investigational but has shown groundbreaking results in Phase II trials, with potential to become a new class leader in fat loss and metabolic support research.\r\n\r\n<strong>Uuringutes tavaliselt t\u00e4heldatud m\u00f5jud on:<\/strong>\r\n<ul>\r\n \t<li>Iiveldus<\/li>\r\n \t<li>K\u00f5hukinnisus<\/li>\r\n \t<li>S\u00f6\u00f6giisu p\u00e4rssimine<\/li>\r\n \t<li>Need on tavaliselt annusest s\u00f5ltuvad ja v\u00e4henevad pikaajalistes uuringutes aja jooksul.<\/li>\r\n<\/ul>\r\n<strong>Kasutusjuhend:<\/strong>\r\n<ul>\r\n \t<li>Rakenda kontrollitud laboritingimustes, mis on keskendunud rasvumisele, insuliiniresistentsusele v\u00f5i energiainevahetusele.<\/li>\r\n \t<li>Tagage reprodutseeritavuse tagamiseks steriilne tehnika, k\u00fclmaahelas hoidmine ja protokollidokumentatsioon.<\/li>\r\n<\/ul>\r\n<strong>Oluline meeldetuletus:<\/strong>\r\n\r\nK\u00f5ik arutatud peptiidid on m\u00f5eldud rangelt ainult laboratoorseks uurimist\u00f6\u00f6ks. Need ei ole heaks kiidetud inimestele manustamiseks, v\u00e4lja arvatud reguleeritud kliiniliste uuringute v\u00f5i retseptiravimite kontekstis.\r\n<h2>Parimad GLP-1 peptiidid uuringute jaoks<\/h2>\r\nGLP-1 peptiidid on teinud revolutsiooni ainevahetuse ja rasvumisega seotud uuringutes. J\u00e4rgmised peptiidid paistavad silma oma p\u00f5hjalikult dokumenteeritud efektiivsusega prekliinilistes ja kliinilistes mudelites:\r\n<ul>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/et\/product\/buy-semaglutide-5mg\/\"><strong>Semaglutiid<\/strong><\/a> \u2013 Laialdaselt uuritud GLP-1 retseptori agonist, mis on tuntud oma rolli poolest s\u00f6\u00f6giisu v\u00e4hendamisel, gl\u00fckoosi tasakaalu reguleerimisel ja rasvkoe massi v\u00e4hendamisel. Pikaajalistes rasvumisuuringutes on see n\u00e4idanud j\u00e4rjepidevat ~15% kehakaalu langust.<\/li>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/et\/product\/buy-tirzepatide-5mg\/\"><strong>Tirtsepatiid<\/strong><\/a> \u2013 Kahetoimeline GLP-1\/GIP-agonist, mis suurendab insuliinitundlikkust ja v\u00e4hendab kehakaalu isegi t\u00f5husamalt kui semaglutidiid. Kliinilistes uuringutes, nagu SURMOUNT-1, t\u00e4heldati ravitud patsientidel keskmiselt 22,51 TP3T kehakaalu langust.<\/li>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/et\/product\/buy-retatrutide-5mg\/\"><strong>Retatrutiid<\/strong><\/a> \u2013 Uue p\u00f5lvkonna kolmekordne agonist, mis m\u00f5jutab GLP-1-, GIP- ja gl\u00fckagooniretseptoreid. Varased uuringud n\u00e4itavad kuni 24,21 TP3T rasva kadu, mis teeb sellest \u00fche k\u00f5ige t\u00f5husama peptiidi praeguses rasvumise uurimist\u00f6\u00f6s.<\/li>\r\n<\/ul>\r\n<h2>Labori kasutamine ja rekonstitueerimine<\/h2>\r\nGLP-1 peptiidid, nagu semaglutiid, tirsepatiid ja retafrutiid, peavad stabiilsuse ja t\u00e4psuse tagamiseks teadusuuringutes olema n\u00f5uetekohaselt lahustatud ja k\u00e4ideldud steriilsetes laboritingimustes.\r\n\r\n<strong>Taaslahustamine<\/strong>Enamikku GLP-1 peptiide saab lahustada bakteriostaatilise vee v\u00f5i steriilse f\u00fcsioloogilise lahusega. Vahu tekkimise v\u00e4ltimiseks s\u00fcstige lahusti aeglaselt viaali sisesseina m\u00f6\u00f6da ja p\u00f6\u00f6rake viaali ettevaatlikult, kuni see on t\u00e4ielikult lahustunud.\r\n\r\n<strong>Hoiustamine<\/strong>:\r\n<ul>\r\n \t<li>L\u00fcofiliseeritud peptiide v\u00f5ib s\u00e4ilitada toatemperatuuril ja valguse eest kaitstult.<\/li>\r\n \t<li>Lahustatud peptiidid p\u00fcsivad stabiilsena 30\u201360+ p\u00e4eva, kui neid hoitakse k\u00fclmkapis temperatuuril 2\u20138 \u00b0C.<\/li>\r\n<\/ul>\r\n<strong>Annustamine prekliinilistes mudelites:<\/strong>\r\n\r\nTavaline annus on hiirtel v\u00f5irottidel 0,01\u20130,2 mg\/kg, s\u00f5ltuvalt katse \u00fclesehitusest ja uuringu eesm\u00e4rkidest.\r\n<h3>T\u00fc\u00fcpilised uuringute l\u00f5pp-punktid:<\/h3>\r\n<ul>\r\n \t<li>Kehakaalu j\u00e4lgimine aja jooksul<\/li>\r\n \t<li>S\u00f6\u00f6giisu p\u00e4rssimine ja toidutarbimise j\u00e4lgimine<\/li>\r\n \t<li>Gl\u00fckoositaluvuse testid<\/li>\r\n \t<li>Rasvapadja massi ja koostise anal\u00fc\u00fcs<\/li>\r\n \t<li>Inkretiinhormoonide aktiivsus, sealhulgas insuliini, GLP-1, GIP ja gl\u00fckagooni m\u00e4\u00e4ramised<\/li>\r\n<\/ul>\r\nNeed peptiidid on m\u00f5eldud \u00fcksnes laboriuuringuteks ja kogu k\u00e4itlemine peab j\u00e4rgima eetilisi protokolle ning steriilseid parimaid tavasid.\r\n<h2>Korduma kippuvad k\u00fcsimused<\/h2>\r\n<h3>Milline GLP-1 peptiid p\u00f5hjustab suurimat rasvakaotust?<\/h3>\r\nRetatrutide on varastes kliinilistes uuringutes n\u00e4idanud k\u00f5ige m\u00e4rkimisv\u00e4\u00e4rsemat kehakaalu langust (~24%).\r\n<h3>Kas peptiide saab paremate tulemuste saavutamiseks kombineerida?<\/h3>\r\nTavaliselt mitte. Retatrutiid aktiveerib juba GLP-1, GIP-i ja gl\u00fckagooni retseptoreid, mist\u00f5ttu on t\u00e4iendav kombineerimine ebavajalik.\r\n<h3>Mida peaks ma tegema, kui peptiid ei lahustu t\u00e4ielikult?<\/h3>\r\nKeerutage viaali ettevaatlikult, \u00e4rge loksutage. Lahustumist v\u00f5ib h\u00f5lbustada kerge soojendamine (37 \u00b0C veevannis).\r\n<h3>Kas nendel peptiididel on retseptori afiinsuses erinevusi?<\/h3>\r\nYes. Semaglutide selectively targets GLP-1 receptors, while Tirzepatide and Retatrutide act on multiple receptors for a broader effect.\r\n\r\nTo finish up, GLP-1 peptides represent a leading edge in metabolic research, offering compelling avenues to study fat loss, insulin regulation, and appetite suppression. Peptides such as Semaglutide, Tirzepatide, and Retatrutide have shown significant effects in both preclinical and clinical models, making them valuable tools for obesity and diabetes-related investigations.\r\n\r\nExplore the full GLP-1 peptide catalog at CellPeptides to support your next metabolic research project.\r\n\r\n<\/div>","link":"https:\/\/cellpeptides.com\/et\/purpose\/glp-1-peptides\/","name":"GLP-1 uurimispeptiidid","slug":"glp-1-peptides","taxonomy":"product_cat","parent":0,"meta":[],"menu_order":0,"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides<\/title>\n<meta name=\"description\" content=\"Shop GLP-1 receptor agonists for appetite, glucose &amp; metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA &amp; EU\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cellpeptides.com\/et\/purpose\/glp-1-peptides\/\" \/>\n<meta property=\"og:locale\" content=\"et_EE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides\" \/>\n<meta property=\"og:description\" content=\"Shop GLP-1 receptor agonists for appetite, glucose &amp; metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA &amp; EU\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cellpeptides.com\/et\/purpose\/glp-1-peptides\/\" \/>\n<meta property=\"og:site_name\" content=\"CellPeptides\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"CollectionPage\",\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/\",\"url\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/\",\"name\":\"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides\",\"isPartOf\":{\"@id\":\"https:\/\/cellpeptides.com\/#website\"},\"description\":\"Shop GLP-1 receptor agonists for appetite, glucose & metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA & EU\",\"breadcrumb\":{\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb\"},\"inLanguage\":\"et\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cellpeptides.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GLP-1 Research Peptides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cellpeptides.com\/#website\",\"url\":\"https:\/\/cellpeptides.com\/\",\"name\":\"CellPeptides\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/cellpeptides.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cellpeptides.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"et\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cellpeptides.com\/#organization\",\"name\":\"CellPeptides\",\"url\":\"https:\/\/cellpeptides.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"et\",\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"contentUrl\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"width\":697,\"height\":152,\"caption\":\"CellPeptides\"},\"image\":{\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Osta GLP-1 peptiide ainevahetusuuringuteks (in-vitro) \u2013 CellPeptides","description":"Osta GLP-1 retseptori agoniste s\u00f6\u00f6giisu, gl\u00fckoosi ja ainevahetuse uuringute jaoks \u2013 Semaglutiid, Tirsepatiid, Retatrutiid. Kiire tarne USA-s ja EL-is","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cellpeptides.com\/et\/purpose\/glp-1-peptides\/","og_locale":"et_EE","og_type":"article","og_title":"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides","og_description":"Shop GLP-1 receptor agonists for appetite, glucose & metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA & EU","og_url":"https:\/\/cellpeptides.com\/et\/purpose\/glp-1-peptides\/","og_site_name":"CellPeptides","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"CollectionPage","@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/","url":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/","name":"Osta GLP-1 peptiide ainevahetusuuringuteks (in-vitro) \u2013 CellPeptides","isPartOf":{"@id":"https:\/\/cellpeptides.com\/#website"},"description":"Osta GLP-1 retseptori agoniste s\u00f6\u00f6giisu, gl\u00fckoosi ja ainevahetuse uuringute jaoks \u2013 Semaglutiid, Tirsepatiid, Retatrutiid. Kiire tarne USA-s ja EL-is","breadcrumb":{"@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb"},"inLanguage":"et"},{"@type":"BreadcrumbList","@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cellpeptides.com\/"},{"@type":"ListItem","position":2,"name":"GLP-1 Research Peptides"}]},{"@type":"WebSite","@id":"https:\/\/cellpeptides.com\/#website","url":"https:\/\/cellpeptides.com\/","name":"Rakupeptiidid","description":"","publisher":{"@id":"https:\/\/cellpeptides.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cellpeptides.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"et"},{"@type":"Organization","@id":"https:\/\/cellpeptides.com\/#organization","name":"Rakupeptiidid","url":"https:\/\/cellpeptides.com\/","logo":{"@type":"ImageObject","inLanguage":"et","@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/","url":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","contentUrl":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","width":697,"height":152,"caption":"CellPeptides"},"image":{"@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/cellpeptides.com\/et\/wp-json\/wp\/v2\/product_cat\/48","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cellpeptides.com\/et\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/cellpeptides.com\/et\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"wp:post_type":[{"href":"https:\/\/cellpeptides.com\/et\/wp-json\/wp\/v2\/product?product_cat=48"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}